Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001992967 | SCV002227671 | uncertain significance | Birt-Hogg-Dube syndrome | 2022-05-31 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with FLCN-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 93 of the FLCN protein (p.Pro93Ser). ClinVar contains an entry for this variant (Variation ID: 1450842). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. |
| Ambry Genetics | RCV003355707 | SCV004053192 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-08-28 | criteria provided, single submitter | clinical testing | The p.P93S variant (also known as c.277C>T), located in coding exon 2 of the FLCN gene, results from a C to T substitution at nucleotide position 277. The proline at codon 93 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |